News Briefs: SGR Repeal Passes House; Sorin Buy; TriVascular IPO
This article was originally published in The Gray Sheet
Executive Summary
House passes legislation to repeal the Medical sustainable growth rate formula for physician payments, but with an Obamacare individual mandate delay that will not likely succeed in the Senate. Sorin buys Oscor’s CRM lead business. TriVascular Technologies moves toward initial public offering. More news.
You may also be interested in...
Lawmakers Ease Imaging Provisions In Draft Physician Pay Reform Bill
Senate Finance and House Ways and Means Committee lawmakers issued a revised proposal to overhaul the physician payment sustainable growth rate formula in advance of a Dec. 13 markup. In response to public comment, lawmakers included more restrictions on which imaging services might be subject to appropriate-use criteria requirements.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.